HLS Therapeutics Reports on U.S. FDA Advisory Committee Recommendation for Vascepa
(WorldNews Health)

HLS Therapeutics Reports on U.S. FDA Advisory Committee Recommendation for Vascepa TORONTO, Nov. 15, 2019/CNW/ - HLS Therapeutics Inc. (`HLS` or the `Company`) (TSX:HLS), a specialty pharmaceutical company focusing on central nervous system and cardiovascular markets, announces that the Endocrinologic and Metabolic Drugs Advisory Committee (`EMDAC`) of the U.S. Food and Drug Administration (`FDA`) yesterday voted unanimously (16-0) that Amarin Corporation plc (NASDAQ: AMRN) provided sufficient evidence of efficacy and safety to support the approval of Vascepa® (icosapent ethyl) capsules for an indication and label expansion to reduce the risk of cardiovascular events in high risk patients...